Abstract
Since the early days of gene therapy at the end of the 1980s, both the scientific community and the public have perceived the ethical and social problems intrinsic to this discipline. On one hand, the technologies for gene transfer are still largely experimental and thus pose important safety issues. On the other hand, the objective of several gene therapy applications is the stable modification of the genetic characteristics of an individual. Whether such modification is ethically acceptable and might also be applied to the embryo or fetus before birth, or to the germinal cells, has always been the subject of intense debate. Finally, while gene therapy is largely accepted when its application is to allow survival or improvement in the health of an individual, the gene transfer technologies of this discipline can also be exploited for the improvement of aesthetic appearance or physical and intellectual performance. These, and other major themes currently at the center of the ethical and social debate accompanying the development of gene therapy, are discussed in this chapter.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Further Reading
Caplan AL (2008) If it’s broken, shouldn’t it be fixed? Informed consent and initial clinical trials of gene therapy. Hum Gene Ther 19:5–6
Chan S, Harris J (2006) Cognitive regeneration or enhancement: the ethical issues. Regen Med 1:361–366
Chan S, Harris J (2006) The ethics of gene therapy. Curr Opin Mol Ther 8:377–383
Coutelle C, Themis M, Waddington SN et al (2005) Gene therapy progress and prospects: fetal gene therapy — first proofs of concept — some adverse effects. Gene Ther 12:1601–1607
Deakin CT, Alexander IE, Kerridge I (2009) Accepting risk in clinical research: is the gene therapy field becoming too risk-averse? Mol Ther 17:1842–1848
Harris J, Chan S (2008) Enhancement is good for you!: understanding the ethics of genetic enhancement. Gene Ther 15:338–339
Kahn J (2008) Informed consent in human gene transfer clinical trials. Hum Gene Ther 19:7–8
Kiuru M, Crystal RG (2008) Progress and prospects: gene therapy for performance and appearance enhancement. Gene Ther 15:329–337
Spink J, Geddes D (2004) Gene therapy progress and prospects: bringing gene therapy into medical practice: the evolution of international ethics and the regulatory environment. Gene Ther 11:1611–1616
Wells DJ (2008) Gene doping: the hype and the reality. Br J Pharmacol 154:623–631
Selected Bibliography
Batshaw ML, Wilson JM, Raper S et al (1999) Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD). Hum Gene Ther 10:2419–2437
Frank KM, Hogarth DK, Miller JL et al (2009) Investigation of the cause of death in a gene-therapy trial. N Engl J Med 361:161–169
Grimm D, Streetz KL, Jopling CL et al (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537–541
Kaiser J (2007) Clinical research. Death prompts a review of gene therapy vector. Science 317:580
Reay DP, Bilbao R, Koppanati BM et al (2008) Full-length dystrophin gene transfer to the mdx mouse in utero. Gene Ther 15:531–536
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Italia
About this chapter
Cite this chapter
Giacca, M. (2010). Ethical and Social Problems of Gene Therapy. In: Gene Therapy. Springer, Milano. https://doi.org/10.1007/978-88-470-1643-9_5
Download citation
DOI: https://doi.org/10.1007/978-88-470-1643-9_5
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1642-2
Online ISBN: 978-88-470-1643-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)